As shown in Figure 10, ip administration of IL-1β at day 15 after TNBS induced colitis led to 90% of colitis recurrence in the SASP treated group, 10% in the Sal B(L) treated group, and 20% in the Sal B(H) treated group. The gene discussed is IL1B; the disease is colitis.